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Annabel Maruani1,2, Mahtab Samimi1,3, Ge´rard Lorette1,3 and Laurence le Cleach4,5
Among the 100 initial priority topics for comparative effectiveness research, three concern topical drugs in the
following dermatologic diseases: psoriasis, chronic lower-extremity wounds (CLEWs), and acne vulgaris (AV). Our
objective was to explore the geometry of the corresponding networks of randomized controlled trials (RCTs). We
performed a review of RCTs on topical drugs in psoriasis, CLEWs, and AV. We searched MEDLINE, Embase, and
CENTRAL for published trials from 2007 to 2012 and ClinicalTrials.gov for unpublished trials registered since 2011.
RCTs comparing at least one topical treatment with any active or inactive comparator, regardless of RCT design
and outcomes, were eligible. We produced network graphs (each node representing a treatment and links
between nodes representing trials) and tested for co-occurrence (preference or avoidance of specific
comparisons). We included 60 RCTs on psoriasis (14,255 patients) and 19 registered RCTs, 50 of CLEWs (5,916
patients) and 7 registered RCTs, and 90 of AV (22,984 patients) and 21 registered RCTs. Head-to-head comparisons
were made in 78%, 32%, and 57% of published RCTs of these conditions, respectively. The co-occurrence test
suggested that no specific head-to-head comparison was significantly preferred or avoided (P-value¼ 0.53, 0.20,
and 0.57, respectively). This study has limitations, the main being that the search period was restricted to 5 years.
In conclusion, more comparative effectiveness trials are needed for CLEWs, for which head-to-head comparisons
are fewer than those for psoriasis and AV.
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INTRODUCTION
Comparative effectiveness research (CER) fosters ‘‘the conduct
and synthesis of research comparing the benefits and harms of
different interventions and strategies to prevent, diagnose,
treat, and monitor health conditions in real world settings’’
(Sox and Greenfield, 2009; Nambudiri and Qureshi, 2013).
The Institute of Medicine for the CER initiative, launched in
2009, established 100 initial priority topics. Topics were
ranked by quartiles. Among them, three directly concerned
the assessment of topical treatments in dermatologic con-
ditions: psoriasis (2nd quartile), chronic lower-extremity
wounds (CLEWs, 3rd quartile), and acne vulgaris (AV) (4th
quartile) (IOM (Institute of Medicine), 2009).
Topical drugs are widely used in dermatology for most skin
conditions such as inflammatory and infectious cutaneous
diseases. They are the mainstay of treatment for most patients
with mild to moderately severe conditions, for which they can
be used alone or in association with a cosmetic product or a
combination of topical treatments. For moderate-to-severe
conditions, systemic drugs are required and are often com-
bined with topical drugs (Lapolla et al., 2011; Seite´ et al.,
2012; Kivelevitch et al., 2013). A multitude of topical drugs
are in the market and have a real economic impact. For
instance, the estimated market value of topical agents for
psoriasis in 2008 was $850 million (Melnikova, 2009). When
multiple treatments are available for a given condition,
dermatologists and patients should be able to identify which
treatments work best, and decision making should be
informed by evidence from randomized controlled trials
(RCTs) (Wan et al., 2012; Zenilman et al., 2013).
In this framework, comparisons of RCTs investigating
different interventions for a given condition constitute a trial
network (Salanti et al., 2008). Examining such a network
allows for assessing which topical treatments have been
compared head to head and which have been compared
with an inactive control (vehicle or placebo) or a common
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comparator (e.g., a systemic treatment) (Mills et al., 2013).
It also allows for assessing the overall amount of evidence
in the trial network and whether some comparisons are
overrepresented.
We aimed to perform a network analysis of RCTs on topical
drugs for psoriasis, CLEWs, and AV published during a recent
5-year period. In particular, we sought to determine the
number of topical drugs used for each of these conditions,
whether some are disproportionately preferred or neglected
in clinical trials, and the proportion of trials using inactive
comparators so as to detect gaps in the existing evidence
that should dictate the future research agenda (Ioannidis
and Karassa, 2010). Moreover, we aimed to compare this
published evidence with trials registered in ClinicalTrials.gov
not yet published to determine whether recommendations for
CER have been taken into account.
RESULTS
Search results for psoriasis, CLEWs, and AV
We found 60 published trials on psoriasis from 361 initially
searched (14,255 patients, range 5–2,920 per trial), with 19
trials from 117 registered at ClinicalTrials.gov. We included
50 published trials on CLEWs from 169 selected (5,916
patients, range 19–953 per trial), with 7 trials from 124
registered at ClinicalTrials.gov. We included 90 published
trials on AV from 437 selected (22,984 patients, range 13–
3,010 per trial), with 21 trials from 63 registered at Clinical-
Trials.gov (See Supplementary File S1 online).
Characteristics of trials
Trials of psoriasis. The 60 reports on RCTs described 31 different
topical drugs that we classified into 12 therapeutic classes
(Table 1; Supplementary File S3 online): Thirteen reports (22%)
described two-arm studies against an inactive control only and 25
(42%) reported at least one arm compared with an inactive
control (Figure 1a). In total, 21 interventions were assessed: 13
topical drugs alone, 5 combinations of topical drugs, 1 combina-
tion of a topical and a systemic drug, 1 with a no treatment arm,
and 1 inactive control. Because of multi-arm trials, we found
100 randomized comparisons of the 21 interventions. The net-
work of trials had considerable diversity (probability of interspe-
cific encounter (PIE)¼ 0.88). The most-studied interventions were
steroids (4,141 patients), vitamin D (3,652 patients), and vitamin
Dþ steroids (3,801 patients). In all, 38 of the 100 randomized
comparisons were between a topical intervention and an inactive
control, and 29 were between steroids and other topical inter-
ventions. The comparisons between steroids and vitamin D and
those between vitamin D, steroids, or vitamin Dþ steroids and an
inactive control were the most represented, without significant
co-occurrence (C-score 13.3, P¼ 0.53). Among the 19 RCTs
registered in ClinicalTrials.gov, 6 (32%) were two-arm trials
against an inactive control (Figure 1b). The most-studied inter-
ventions were experimental topical drugs. In all, 20 of the 41
(50%) randomized comparisons were between a topical inter-
vention and an inactive control, and 50% were between topical
drugs.
Trials on CLEWs. The 50 reports of RCTs on CLEWs described
44 different topical drugs that we classified into 15 therapeutic
classes (Supplementary File S3 online). The network of trials had
considerable diversity (PIE¼ 0.86). The most-studied interventions
were nonsteroid anti-inflammatory drugs and silver. In all, 41
reports (82%) described at least one inactive control arm: in 34
(68%), the intervention was compared against this inactive
control only. The network was star-shaped, and comparisons
against an inactive control were overrepresented but not signifi-
cantly (C-score 11.2, P¼ 0.20) (Figure 2a). Among the seven trials
registered in ClinicalTrials.gov, five involved a control arm with
an inactive control, which was the only comparator in four cases
(Figure 2b).
Table 1. Characteristics of reports of randomized controlled trials (RCTs) of three dermatologic conditions published
from 2007 to 2012
Characteristics of trials
Psoriasis;
n¼ 60
Chronic lower-extremity
wounds; n¼ 50
Acne vulgaris;
n¼90
Sample size: median (inter-quartile range) 60 (35–217) 59 (40–121) 87 (53–174)
Geographic area
North America 18 (30%) 9 (18%) 36 (40%)
South America 1 4 (8%) 2 (2%)
Asia 19 (32%) 6 (12%) 36 (40%)
Europa 22 (37%) 28 (56%) 16 (18%)
Oceania 0 2 (4%) 0
Africa 0 1 0
Multicentric trial 28 (47%) 30 (60%) 47 (52%)
Design of the trial
Parallel 47 (78%) 50 (100%) 79 (88%)
Split body 13 (22%) 0 11 (12%)
Multi-arm (42) trials 16 (27%) 7 (14%) 22 (24%)
Comparison involving a combination of topical drugs in at least one arm 17 (28%) 3 (6%) 35 (39%)
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Figure 1. Psoriasis—60 published trials; 19 registered trials. Networks of drugs assessed for psoriasis in reports of randomized controlled trials (RCTs) (a) and trials
registered in ClinicalTrials.gov (b). Nodes represent the interventions—two nodes are linked together by a line (edge) if at least one trial compared the two
corresponding interventions. The size of a node is proportional to the total number of patients randomly allocated. The thickness of an edge is proportional to the
number of randomized comparisons between the two corresponding interventions. Loops (connecting a node to itself) represent intra-drug comparisons (e.g.,
doses). Drugs were applied topically unless indicated as oral. MTX, methorexate; Vit, vitamin; rhEGF, recombinant human epidermal growth factor; Exp,
experimental (new drugs from a non-specified class).
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Figure 2. Chronic lower-extremity wounds—50 published trials; 7 registered trials. Networks of drugs assessed for chronic lower-extremity wounds (CLEWs) in
reports of randomized controlled trials (RCTs) (a) and trials registered in ClinicalTrials.gov (b). AB, antibiotics; Exp, experimental; GF, growth factors; NSAID,
nonsteroid anti-inflammatory drugs.
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Trials on AV. The 90 reports of RCTs on AV described 39
different topical drugs that we classified into 14 therapeutic
classes (Supplementary File S3 online). The network of trials
had considerable diversity (PIE¼ 0.89). In all, 51 reports (57%)
described active comparators, with a systemic control arm in two
cases, and 51 (57%) described at least one inactive control arm:
39 (43%) described comparing the intervention against this
inactive control. The most represented comparisons were
between topical antibiotics, benzoyl peroxide, or retinoids and
an inactive control, without significant co-occurrence (C-score
19.0; P¼ 0.57) (Figure 3a). Among the 21 RCTs registered in
ClinicalTrials.gov, 15 involved a control arm with an inactive
control, which was the only comparator in five cases (Figure 3b).
DISCUSSION
We studied the network of evidence from RCTs on topical
drugs for psoriasis, CLEWs, and AV. Reports of RCTs were
more numerous for AV than for the other conditions (90 versus
50 and 60, respectively), and studies included a larger number
of patients. This finding can be explained by the high
frequency of AV in the population (Ghodsi et al., 2009). All
networks showed substantial diversity, which is explained by
the variety of topical drugs available for these conditions and
assessed in RCTs. Indeed for CLEWs, we identified 15 thera-
peutic classes for 50 trials. Clinical research on this prevalent
and painful condition may be constantly driven by the suc-
cessive topical and even systemic treatments showing
disappointing results. CLEWs remain a medical problem of
high priority.
Trials that randomize patients to alternative treatments, each
with the potential to be the best practice, are fundamental to
CER. In our study, comparisons with inactive controls were
frequent, especially for CLEWs. In published RCTs, two-arm
trials with an inactive control arm represented 22% of reports
on psoriasis RCTs, 68% of CLEWs, and 43% of AV RCTs.
Although we lack a standard to establish whether a percentage
of trials with an inactive control is adequate or not, considering
that more than one-third is inadequately high seems relevant. In
RCTs of psoriasis, a previous review of publications from 2001
to 2005 showed a high rate of use of placebo (38.5% of trials,
corresponding to 58.3% of subjects), but topical and systemic
treatments were not analyzed separately (Katz et al., 2006).
Calculations of C-scores, reflecting degrees of co-occur-
rence of interventions assessed, were not statistically significant
for the three studied conditions, i.e, we found no head-to-head
comparisons that were specifically preferred or avoided.
Therefore, our results do not suggest a substantial lack of
head-to-head evidence for mild psoriasis and AV, but for
CLEWs results are more questionable. Although we demon-
strated no significant avoidance of comparisons in trials on
CLEWs, inactive controls were highly represented. Also, as
clinicians, we noted only a few comparisons of drugs with a
close mode of action, such as antiseptics and nonsteroid
anti-inflammatory drugs, antibiotics and silver, or protease
inhibitors and growth factors.
In other conditions, the lack of head-to-head trials was more
evident (Kim et al., in press; Rizos et al., 2011; Kappagoda and
Ioannidis, 2012; Estellat and Ravaud, 2012; Tonelli et al.,
2013; Ioannidis et al., 2013). For instance, in arthritis,
researchers have shown greater lack of head-to-head trials
on arthritis psoriasis than we observed for cutaneous psoriasis
treated with topical drugs, although arthritis psoriasis is a
condition of high functional severity (Estellat and Ravaud,
2012; Ioannidis et al., 2013).
When comparing published RCTs with registered trials not
yet published, the proportions of head-to-head trials were
similar. Thus, the inactive control remains the preferred com-
parator, although ethical problems linked to the choice of an
inactive comparator has been highlighted, despite the CER
initiative (Hochman and McCormick, 2010). The use of inac-
tive control could be preferred because of compliance with
regulatory recommendations to ensure that treatment effects
are well documented, because of the low cost of using a
placebo, and because of trials of inactive comparators more
likely than those of active comparators to report positive
results (Hochman and McCormick, 2010).
The inactive controls used consisted of topical vehicles or
emollients. Although we found high representation of compar-
isons with inactive controls, these may not be true placebos
because they are not totally inactive despite their lack of
active principle (Shamsudin and Fleischer, 2010). Indeed,
applying excipients on the skin induces physiochemical
modifications of the skin barrier, which were demonstrated
with transepidermal water loss (Hon et al., 2013). We found
the use of inactive controls particularly frequent in studies on
CLEWs. Similarly, dressings without the active principle,
always used as inactive control in CLEWs trials, may not be
true placebos.
Our analysis has some limitations. The most important one
was that the search was limited to articles published over 5
years, and the best time to search for the deliberate avoidance
of key comparisons is probably when new drugs are intro-
duced. Therefore, studying older reports of RCTs may reveal
increased diversity or co-occurrence. However, we aimed to
cover a time window around when the CER initiative was
launched, in 2009 (Clancy, 2012). Second, our network of
published evidence may have been affected by reporting bias.
Third, we focused the study on topical drugs, although systemic
drugs may also be given in moderate conditions and are more
expensive in many cases. The reason for this restriction was to
increase homogeneity of the studied population and avoid
disjointed networks of trials. Fourth, we did not assess the
sponsorship of the study; studies with industry sponsorship are
more likely to use inactive comparators for several conditions
(Katz et al., 2006; Bourgeois et al., 2012; Dunn et al., 2012;
Stamatakis et al., 2013). However, 87% of our selected trials
registered in ClinicalTrials.gov had industry sponsorship.
Moreover, our study did not allow for assessing the
avoidance of comparisons of manufactured combinations of
drugs and the active components separately. This analysis
would have been interesting because the latter drugs are less
costly (Williams et al., 2012). Finally, we included all RCTs
regardless of outcomes and follow-up duration. The nature of
the networks may evolve depending on the outcome of
interest (e.g., efficacy or safety) and according to treatment
duration (e.g., short-term or long-term treatment).
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Figure 3. Acne vulgaris—90 published trials; 21 registered trials. Networks of drugs assessed for acne vulgaris in reports of randomized controlled trials (RCTs) (a)
and trials registered in ClinicalTrials.gov (b). AB, antibiotics; BZPO, benzoyl peroxide; NSAID, nonsteroid anti-inflammatory drugs; Exp, experimental.
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In conclusion, for three dermatologic topics (psoriasis,
CLEWs, and AV) on mild-to-moderate severity with respect
to topical treatments, our network analysis of RCTs with
published results and ongoing RCTs did not find a significant
preference or avoidance of specific comparisons. However,
it showed that comparisons with inactive controls were
more frequent than were head-to-head trials, especially for
CLEWs, for which more comparative effectiveness trials are
needed.
MATERIALS AND METHODS
We systematically searched for RCTs that assessed topical drugs in
psoriasis, CLEWs, and AV, with results published during a recent
5-year period (from 1 January 2007 to 28 July 2012) or registered in
ClinicalTrials.gov (from 1 January 2011 to 28 July 2012).
Selection criteria
We considered RCTs that assessed any topical treatment of three
conditions: cutaneous psoriasis, CLEWs, or AV. Cutaneous psoriasis
included plaque, guttate, or pustular psoriasis and body, scalp,
palmo-plantar, or ungueal topography. CLEWs included arterial,
diabetic, and vasculitic leg ulcers. We included trials on AV but
not closely related conditions (e.g., acne rosacea). Eligible trials
compared in at least one arm a topical treatment with any active or
inactive comparator, regardless of RCT design and outcomes. Multi-
dose trials were eligible. We focused on topical drugs because of the
following reasons: (1) they are the first-line treatment for the studied
dermatologic conditions; (2) they constitute a great amount of
prescriptions and represent a major cost to the public; (3) apart from
the cost, a very large population is exposed to topical drugs; and (4)
we could restrict the study to a homogeneous group of patients (e.g.,
with mild to moderately severe conditions).
We excluded non-randomized trials, trials on healthy volunteers,
and interventional trials of treatments other than drugs; in particular,
we excluded trials of devices, which are numerous in CLEWs,
because we focused on active topical drugs often incorporated in
dressings. We excluded RCTs with results published as abstracts only.
With two publications for one RCT, we included the most recent
publication.
Search strategy
We searched for systematic reviews in the Cochrane Library and
screened lists of trials included in relevant reviews. We also searched
for reports of RCTs in the Cochrane Central Register of Controlled
Trials, in MEDLINE, and in EMBASE. The searches covered the period
from 1 January 2007 to 28 July 2012. Search equations created by an
information specialist (GF) were designed for each condition and
each database (see Supplementary File S2 online). We also searched
ClinicalTrials.gov for RCTs registered from 1 January 2011 to 28 July
2012. We chose to consider RCTs registered after 2011 to avoid
double counting published trials.
Data extraction and categorization of interventions
Selection of trials was performed by one author (AM). For each
selected trial, we extracted information on the first author, publication
year, journal, country/site, trial design (parallel arm, cross-over, or
split body) and number of arms, interventions and comparators, as
well as the number of patients randomly allocated to each arm. Two
authors, who are dermatologists (AM, LLC), independently and in
duplicate classified topical drugs into therapeutic classes (Yu and Van
Scott, 2004, see Supplementary File S3 online). We defined an
inactive control as a topical intervention without the active principle
(vehicle or placebo). Discrepancies in classifying drugs were resolved
with a third dermatologist (GL).
Trial networks
For each condition, we produced networks of RCTs with published
results and registered trials. When a multi-arm trial compared two
interventions belonging to the same therapeutic class (e.g., with
different dosages), we considered the two as one intervention (and we
added the number of patients). We produced network graphs in
which nodes (or vertices) represented the interventions, and lines
linking nodes (edges) indicated that at least one RCT compared the
two interventions linked. The size of a node was proportional to the
total number of patients randomly allocated to the corresponding
intervention. The thickness of an edge was proportional to the
number of randomized comparisons between the two corresponding
interventions. Loops (connecting a node to itself) represent intra-drug
comparisons (e.g., comparisons of the same drug at different doses).
We assessed the network geometry: how many head-to-head
comparisons between interventions were assessed by at least one
trial and how many randomized comparisons were against an
inactive control. We assessed the network diversity, which increases
with the number of interventions in the network and for a given
number of interventions and decreases when the interventions are not
equally represented (Salanti et al., 2008). We calculated the PIE:
values p0.75 are considered to reflect limited diversity (Hurlbert,
1971).We also assessed the degree of co-occurrence, which increases
when particular head-to-head comparisons of specific interventions
are preferred or avoided (Stone and Roberts, 1990). We used the C-
score statistic for co-occurrence (larger values correspond to a larger
degree of co-occurrence) and reported the associated P-values
(Salanti et al., 2008).
Analyses involved the NodeXL add-in for Excel 2007 (Social Media
Research Foundation), R v3.0.2 (R Development Core Team, Vienna,
Austria), and EcoSim v7 (http://www.uvm.edu/Bngotelli/EcoSim/
EcoSim.html).
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